Table 3. HPV-31 and HPV-45 antibody responses for the 3D schedule in women aged 15–25 y and the 2D schedule in girls aged 9–14 y up to month 48 (according-to-protocol month 48 immunogenicity cohort, subjects seronegative at baseline).

Antigen	Timing (months)	3D     20/20 M0,1,6     (women 15–25 y)			2D     20/20 M0,6     (girls 9–14 y)
		N	Seropositive, n (%)	GMT* (95% CI), EU/mL	N	Seropositive, n (%)	GMT* (95% CI), EU/mL
HPV-31	0	36	0 (0.0)	29.5 (29.5, 29.5)	40	0 (0.0)	29.5 (29.5, 29.5)
	7	36	36 (100)	1201.8 (819.2, 1763.0)	40	40 (100)	1321.7 (1011.7, 1726.7)
	12	36	35 (97.2)	370.0 (246.4, 555.6)	40	39 (97.5)	262.4 (197.0, 349.6)
	18	36	35 (97.2)	270.7 (190.9, 383.8)	40	34 (85.0)	184.7 (134.8, 253.0)
	24	36	31 (86.1)	215.2 (145.5, 318.3)	40	35 (87.5)	166.7 (122.8, 226.3)
	36	36	33 (91.7)	237.5 (166.7, 338.4)	39	35 (89.7)	173.7 (126.7, 238.1)
	48	36	32 (88.9)	241.7 (166.7, 350.3)	40	37 (92.5)	195.5 (144.8, 263.9)
HPV-45	0	38	0 (0.0)	29.5 (29.5, 29.5)	37	0 (0.0)	29.5 (29.5, 29.5)
	7	38	38 (100)	928.4 (652.0, 1322.0)	37	37 (100)	1574.5 (1156.8, 2142.8)
	12	38	37 (97.4)	306.1 (207.9, 450.7)	37	35 (94.6)	305.7 (209.3, 446.4)
	18	38	33 (86.8)	204.3 (140.0, 298.2)	37	32 (86.5)	191.6 (133.0, 275.8)
	24	38	33 (86.8)	178.4 (124.8, 254.9)	37	32 (86.5)	176.7 (121.9, 256.3)
	36	38	32 (84.2)	169.3 (117.8, 243.4)	36	31 (86.1)	177.4 (124.4, 252.8)
	48	38	30 (78.9)	147.2 (102.0, 212.5)	37	34 (91.9)	156.6 (114.2, 214.7)

2D, 2-dose schedule; 3D, 3-dose schedule; 20/20, 20 μg each of HPV-16 and -18 L1 virus-like particles; 95% CI, exact 95% confidence interval; EU/mL, ELISA unit per milliliter; GMT, geometric mean antibody titer; M, month; N, number of evaluable seronegative subjects in the according-to-protocol month 48 immunogenicity cohort; n (%), number (percentage) of seropositive subjects with antibody titer greater than or equal to the cut-off value (≥59 EU/mL for HPV-31 and HPV-45). *Antibody titers below the cut-off of the assay were given an arbitrary value of half the cut-off for the purpose of GMT calculation.